Drugs / Tirofiban
Tirofiban
also known as
Tirofiban Hydrochloride · Aggrastat · Agrastat · brand name of tirofiban: Xinweining · L-700,462 · MK-383 · Tirofiban hcl · Tirofiban hydrochloride anhydrous · +1 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | AGGRASTAT | — | 2013-10-10 | fda.gov ↗ |
| Approved | US (FDA) | AGGRASTAT | — | 1998-05-14 | fda.gov ↗ |
Trials 49 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 16 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04111289 Comparator | Nov 2019 → Sep 2021 | — | Assiut University | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01103440 Comparator | Apr 2007 → Jun 2009 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT01660373 Comparator | Aug 2012 → Aug 2013 | acute coronary syndrome | Pusan National University Yangsan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01336348 Comparator | Apr 2010 → Jun 2011 | ST-elevation myocardial infarction | Università degli Studi di Ferrara | Completed | No outcome recorded |
| Phase 3 | NCT00251576 Background | Nov 1999 → Mar 2004 | acute coronary syndrome | Organon and Co | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT06769256 Comparator | Jan 2025 → Dec 2027 expected | ST-elevation myocardial infarction | Henan Institute of Cardiovascular Epidemiology | Recruiting | No outcome recorded |
| Phase 4 | NCT02978040 Comparator | Jul 2017 → Aug 2019 | ST-elevation myocardial infarction, coronary artery disorder | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 4 | NCT02739711 Comparator | Jul 2016 → May 2024 | acute myocardial infarction | University of Luebeck | Unknown | No outcome recorded |
| Phase 4 | NCT02131220 Comparator | Nov 2015 → Aug 2017 | myocardial infarction | Fudan University | Completed | No outcome recorded |
| Phase 4 | NCT01696110 Comparator | Aug 2012 → Jul 2013 | acute myocardial infarction | Shenyang Northern Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02054000 Comparator | Jan 2011 → Dec 2013 | — | TC Erciyes University | Completed | No outcome recorded |
| Phase 4 | NCT00566891 Comparator | Dec 2007 → Jul 2008 | coronary artery disorder | S. Anna Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00538317 Comparator | Jul 2007 → Nov 2008 | acute myocardial infarction | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 4 | NCT00790387 Comparator | Jun 2004 → Dec 2005 | acute coronary syndrome | The Prince Charles Hospital | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06045156 Comparator | Apr 2024 → Jan 2026 overdue | ischemic stroke | The First Hospital of Jilin University | Recruiting | No outcome recorded |
| — | NCT05902000 Background | Jun 2023 → Jun 2025 | occlusion precerebral artery, stroke disorder | Xueli Cai | Unknown | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 66 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tirofiban | “Intracoronary cocktail (tirofiban, bivalirudin, tenecteplase) injection combined with thrombus aspiration” NCT02592694 ↗63“Patients in the treatment group (n = 62) received eptifibatide (n = 41) or tirofiban (n = 21).” PMID 39217605 ↗ Dec 2024 “Tirofiban is a platelet glycoprotein IIb/IIIa receptor antagonist” NCT06373042 ↗ “Tirofiban is used as an adjunct to endovascular therapy.” NCT05902000 ↗ “cocktail (tirofiban, bivalirudin, tenecteplase)” NCT02592720 ↗ “Tirofiban” NCT01103440 ↗ |
| Known as | Aggrastat | “Tirofiban (Aggrastat) will be dosed as a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.” NCT01245725 ↗1“tirofiban hydrochloride (AGGRASTAT®)” NCT03691727 ↗ |
| Known as | Agrastat | “tirofiban (Agrastat®)” NCT00445263 ↗ |
| Known as | brand name of tirofiban: Xinweining | “brand name of tirofiban: Xinweining” NCT01696110 ↗ |
| Known as | L-700,462 | ChEMBL registry synonym — accepted as the source's own label CHEMBL916 ↗ |
| Known as | MK-383 | ChEMBL registry synonym — accepted as the source's own label CHEMBL916 ↗ |
| Known as | Tirofiban hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL916 ↗ |
| Known as | Tirofiban Hydrochloride | “tirofiban hydrochloride (AGGRASTAT®)” NCT03691727 ↗ |
| Known as | Tirofiban hydrochloride anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL916 ↗ |
| Known as | Tirofiban hydrochloride monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL916 ↗ |
| Action | Inhibit | “Tirofiban is another potent inhibitor of GP IIb/IIIa platelet receptor” NCT00383136 ↗ |
| Modality | Other / unclassified | “glycoprotein inhibitor, Tirofiban” NCT00407771 ↗ |
| Route | Intravenous | “intravenous infusion” NCT00445263 ↗ |